

IDAHO BOARD OF OPTOMETRY
Division of Occupational and Professional Licenses
11341 W. Chinden Blvd.
Boise, ID 83714

Board Meeting Minutes of 7/18/2022

BOARD MEMBERS PRESENT: Terri L. Haley, O.D. - Chair
Jared Walker, O.D.
Shawn Sorenson O.D
Lance W. Fagan, O.D.
Joshua Sears, JD

DIVISION STAFF: Katie Stuart, Executive Officer
Lea Kear, Legal Counsel
Jan Arrasmith, Practice and Education Specialist
Susan Cassell, Board Support Specialist
Susan Villanueva, Board Support Specialist

OTHERS PRESENT: Lisa White, Idaho Optometric Association
Lance Giles, The Giles Group
Vibaldo Torres, Pharmacy Student

CONVENED: Terri L. Haley, O.D. called the meeting to order at 8:31 AM MT.

OPENING STATEMENT

Katie Stuart read the opening statement following roll call.

BOARD BUSINESS

Ms. Stuart reviewed the procedure for Zero Based Regulation (ZBR) for Administrative Rules review.

Rule 600: Ms. Stuart presented the newly revised Rule regarding Optometrist use of pharmaceutical agents. Dr. Sorenson stated that the few Idaho Optometrists who are restricted in prescribing privileges have licenses that will expire soon, he suggested simplified language allowing Optometrists to practice with diagnostic and therapeutic capabilities. Dr. Haley and Dr. Sorenson discussed the confusion over two practice levels as therapeutic agents are incorporated into the practice of Optometry.

600.02 b. ii: Removed duplicate language and will revise language regarding the examination approved by the Association of Regulatory Boards of Optometry (ARBO), as ARBO does not approve testing. Per Dr. Haley, Optometry board testing consists of a three-part test that includes treatment and management of the ocular disease. Dr. Sorenson recommended

removing the 100-hour requirement from **600.02 b. i** because surrounding states do not require it and there is an hour requirement for any testing.

600.01. a: Mr. Sears inquired about language addressing obtaining therapeutic pharmaceutical agents “from any other source”. Board members confirmed that pharmaceutical agents are ordered by each practice from distributors. Ms. Stuart will confer with Dr. Chopski from the Board of Pharmacy for revised language.

The Board reviewed the proposed Rule Chapters as discussed in prior ZBR meetings.

Rule 275: Dr. Haley cited **275.01 b** regarding applicants from any state or country and was not aware of any foreign endorsements. Ms. Stuart will reach out to ARBO and the National Board of Examiners in Optometry (NBEO).

Ms. Stuart stated that license applications include requirements for approved optometry schools. Board members expressed concern about unapproved schools, however, Ms. Stuart informed the Board that they will review the license applications following completion of ZBR.

Rule 300: Dr. Sorenson quoted section 01 regarding “quality continuing education programs”. It was agreed to add “add/or” current proposed language to allow Optometrists to Continuing Education (CE) courses that focus on protecting health and safety and/or contribute to their germane profession. Example: Licensees are responsible for choosing quality continuing education programs that focus on protecting the health and safety of the public and/or contribute to their germane profession. The Board will continue to audit CEs and will continue the conversation on approved courses.

Dr. Haley would like to revamp 300.03 to update language referring to asynchronous and live courses. Ms. Stuart will revise the section for the Board’s review.

Rule 450: Dr. Sorenson stated that contact lens prescriptions are no longer written with lens material information, Dr. Haley concurred; it will be removed from 02. The Board discussed circumstances meriting shorter or longer length of valid prescriptions, Ms. Stuart stated that “at least one year” covers scope of practice.

Rule 600: Dr. Sorenson addressed section 03 under discipline and wanted clarification on how long and what type of records need to be kept, and also to comply with HIPAA. Ms. Kear will review compliance needs and follow up with the Board at a later date.

PUBLIC COMMENTS

No public comments were offered to the Board.

NEXT MEETING DATE: September 19, 2022.

ADJOURNMENT

Dr. Haley adjourned the meeting at 9:50 AM